Trial intelligence / Profile preview

Telavancin vs Vancomycin in cSSSI (ATLAS 2)

NCT00107978Phase 3Completed

Sponsor
Cumberland Pharmaceuticals
Start
Feb 2005
Primary completion
May 2006
Modality
Peptides, Orthosteric Ligands
Countries
1
01

Overview

A Phase 3 trial of telavancin in Skin and Skin Structure Infection (SSSI), sponsored by Cumberland Pharmaceuticals. Started Feb 2005; status: completed.

02

Drugs

telavancin
03

Conditions

Skin and Skin Structure Infection (SSSI)

Beyond the preview

Go deeper on NCT00107978.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00107978.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call